SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 179 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,134 | -58.1% | 1,890,425 | -9.3% | 0.01% | -50.0% |
| Q2 2023 | $2,709 | +17.6% | 2,083,633 | +59.1% | 0.02% | +15.8% |
| Q1 2023 | $2,304 | +234.4% | 1,309,323 | +496.5% | 0.02% | +90.0% |
| Q4 2022 | $689 | -100.0% | 219,519 | -37.8% | 0.01% | -56.5% |
| Q3 2022 | $1,728,000 | +33.1% | 352,730 | +12.5% | 0.02% | +43.8% |
| Q2 2022 | $1,298,000 | +137.7% | 313,442 | +330.5% | 0.02% | +166.7% |
| Q4 2021 | $546,000 | -3.7% | 72,815 | +15.8% | 0.01% | -25.0% |
| Q3 2021 | $567,000 | -24.8% | 62,878 | -0.2% | 0.01% | 0.0% |
| Q2 2021 | $754,000 | +134.2% | 62,991 | +205.6% | 0.01% | +166.7% |
| Q4 2020 | $322,000 | -32.8% | 20,611 | -59.3% | 0.00% | -70.0% |
| Q3 2020 | $479,000 | +470.2% | 50,660 | +404.6% | 0.01% | +400.0% |
| Q4 2019 | $84,000 | -43.6% | 10,039 | -39.0% | 0.00% | -60.0% |
| Q3 2019 | $149,000 | +26.3% | 16,470 | +49.7% | 0.01% | 0.0% |
| Q2 2019 | $118,000 | – | 11,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |